evipedia.ai
← Back

Evolocumab vs. Alirocumab for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L / Opus 5.5

Also known as: Evolocumab, Repatha, AMG 145, Alirocumab, Praluent, REGN727, SAR236553

Motivation

Evolocumab (Repatha) and alirocumab (Praluent) are lab-made antibodies that switch off a liver protein which otherwise limits how much cholesterol the liver pulls out of the blood. Both are given as an injection every two to four weeks to lower the cholesterol-carrying particles that build plaque inside artery walls. For health- and longevity-focused adults they matter because artery disease remains a leading cause of death and disability, shaped by lifetime exposure to these particles.

The two drugs reached the market within weeks of each other in 2015, growing out of studies of people born with an inactive copy of this protein’s gene, whose lifelong cholesterol levels and heart health drew intense research interest. Each drug was tested in its own large trial tracking heart attacks, strokes and deaths, in different patient groups with different dosing strategies; the two have never been compared in a large head-to-head trial.

This review examines the evidence for and against each drug as a long-term tool for heart health and longevity: how they compare on cardiovascular outcomes and survival, on side effects, dosing and cost, and where the evidence for one differs from the other.

Benefits - Risks - Protocol - Conclusion

Expert commentary and key primary analyses that frame how evolocumab and alirocumab compare and where their evidence diverges.

Explains how PCSK9 (proprotein convertase subtilisin/kexin type 9, a liver protein that destroys cholesterol-clearing receptors) inhibitors work, tracing the class from gene discovery through evolocumab, alirocumab and one-time gene editing.

Compares PCSK9 inhibitors with bempedoic acid and ezetimibe, explaining how blocking PCSK9 preserves the liver’s receptors for LDL (low-density lipoprotein, the main cholesterol-carrying particle), and reviews evolocumab’s FOURIER outcome and EBBINGHAUS cognitive-safety results.

Details ODYSSEY OUTCOMES’ all-cause death signal after acute coronary syndrome (heart attack or unstable chest pain), funded by alirocumab’s makers Sanofi and Regeneron, noting it fell outside the trial’s planned testing order.

Independent readjudication of death narratives from FOURIER, funded by evolocumab’s maker Amgen, reporting numerically more cardiac deaths with evolocumab; the main skeptical counterpoint in the mortality comparison.

Editorial arguing that apparent differences in LDL-C (cholesterol carried in LDL particles) benefit reflect trial populations, follow-up and titration (stepwise dose adjustment) strategy, not molecule biology.

Content from Andrew Huberman, Chris Kresser, Life Extension Magazine and Lifespan.io was not included because their sites mention PCSK9 inhibitors only in passing, predate the drugs, or (for Huberman Lab) appear only as AI-generated summaries.

Grokipedia

Machine-written encyclopedia entry summarizing evolocumab’s antibody type, Amgen development, dosing, 2015 US approval and FOURIER results; useful quick background, with only a brief paragraph comparing it with alirocumab.

Companion entry covering alirocumab’s Regeneron–Sanofi development, 2015 approval, later indication expansions and ODYSSEY OUTCOMES; Grokipedia has no dedicated article comparing the two drugs.

Examine

No Examine article exists for evolocumab or alirocumab. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article exists for evolocumab or alirocumab; evolocumab appears only in a clinical update inside ConsumerLab’s red yeast rice review. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Network meta-analyses (statistical comparisons linking separate trials through their shared placebo groups), a Cochrane review and safety meta-analyses comparing the two antibodies’ effects on cardiovascular events, death and adverse events.

Across 30 trials, alirocumab showed lower all-cause death than evolocumab (relative risk, the ratio of event rates, 0.80) but more injection-site reactions; populations differed markedly.

Updated 26-trial network analysis: no difference in major cardiovascular events; alirocumab’s lower death rate (relative risk 0.84) was not statistically significant.

Cochrane review of 24 trials: high-certainty event reduction with both drugs, mortality reduction with alirocumab only, minimal evidence in lower-risk people.

Across 85,123 adults: no excess new diabetes, cognitive or liver harm; more injection-site reactions; early worsening of existing diabetes with evolocumab.

Twenty-one trials with 59,733 patients showed no increase in neurocognitive adverse events overall or for either drug separately.

Mechanism of Action

Both drugs are fully human monoclonal antibodies (lab-made antibodies engineered to bind a single target) against PCSK9. Circulating PCSK9 attaches to LDL receptors on liver cells and escorts them to lysosomes (the cell’s disposal compartments); blocking it lets each receptor return to the cell surface many more times, so the liver clears more LDL and other particles carrying apolipoprotein B (apoB, the structural protein on every artery-clogging lipoprotein). LDL cholesterol falls by 50–60% on top of a statin (a drug class that blocks the liver’s cholesterol production), and lipoprotein(a) [Lp(a), an inherited LDL-like particle that promotes plaque and clotting] falls by 20–30%. How Lp(a) falls is contested: one explanation is increased receptor-mediated clearance, the other reduced particle production.

Evolocumab is an IgG2 and alirocumab an IgG1 antibody (immunoglobulin G subclasses). Both bind PCSK9 selectively and stay mainly in the bloodstream. Neither is metabolized by CYP enzymes (the liver enzyme family that breaks down most oral medications); both are degraded like other proteins, through saturable binding to PCSK9 at low concentrations and general protein breakdown at higher ones. Per the Repatha prescribing information, evolocumab peaks in 3–4 days, has 72% bioavailability (share of a dose reaching the blood) and a half-life (time for blood levels to halve) of 11–17 days. Per the Praluent prescribing information, alirocumab peaks in 3–7 days, has about 85% bioavailability and a 17–20-day half-life, shortened to about 12 days alongside a statin because statins raise PCSK9 levels.

Historical Context & Evolution

PCSK9 was linked to cholesterol in 2003, when French researchers found gain-of-function (overactivating) mutations in families with familial hypercholesterolemia (inherited, very high LDL cholesterol). In 2006, Cohen et al. reported that people carrying loss-of-function (disabling) PCSK9 variants had 15–28% lower LDL cholesterol and 47–88% fewer coronary events over 15 years, making PCSK9 one of the fastest gene-to-drug targets.

Amgen developed evolocumab; Regeneron and Sanofi developed alirocumab. The US Food and Drug Administration (FDA) approved alirocumab in July 2015 and evolocumab in August 2015, originally to lower LDL cholesterol in familial hypercholesterolemia or established artery disease when statins were insufficient, at list prices of about $14,000 per year. Outcome trials followed: FOURIER for evolocumab (2017) and ODYSSEY OUTCOMES for alirocumab (2018), each funded by the respective manufacturer. Early open-label reports of memory complaints (open-label: unblinded) prompted a dedicated cognition trial, which found no difference.

High prices and insurer restrictions limited uptake until both list prices were cut by about 60% in 2018–2019. The companies’ patent dispute ended in 2023, when the US Supreme Court invalidated Amgen’s broad antibody patent claims. Interest for health optimization grew from genetic evidence that lifelong low LDL is protective, from analyses showing continued benefit at LDL levels below 30 mg/dL, and from the 2025 VESALIUS-CV trial of evolocumab in people without a prior heart attack or stroke. Opinion has shifted toward earlier, more intensive use, while independent reanalyses continue to question the published mortality data.

Expected Benefits

High 🟩 🟩 🟩

Lower LDL Cholesterol and ApoB

Both antibodies cut LDL cholesterol by roughly 55–60% on top of statins, with parallel falls in apoB and non-HDL cholesterol (cholesterol in all particles except protective high-density lipoprotein). The effect is evident within 2–4 weeks and was sustained for up to 8.4 years with evolocumab in the FOURIER open-label extension. Evidence comes from dozens of randomized trials of each agent. An Amgen-authored network meta-analysis ranked evolocumab and alirocumab 150 mg as the most effective regimens, ahead of alirocumab 75 mg and 300 mg monthly.

Magnitude: Evolocumab lowered LDL cholesterol 59% versus placebo (median 92 → 30 mg/dL) in FOURIER; alirocumab 150 mg every 2 weeks lowered it 62 percentage points versus placebo at 24 weeks in ODYSSEY LONG TERM.

Fewer Heart Attacks, Strokes and Coronary Procedures

Both drugs reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death and related hospitalizations or procedures) by about 15–25% relative to placebo when added to statins. Evolocumab was tested in stable artery disease (FOURIER) and in 12,257 people without prior heart attack or stroke (VESALIUS-CV); alirocumab was tested after recent acute coronary syndrome (ODYSSEY OUTCOMES). All three trials were manufacturer-funded. Indirect comparison finds no difference between the agents for these events, and absolute benefit scales with baseline risk.

Magnitude: Evolocumab hazard ratio (HR, the relative event rate over time; 0.85 means 15% fewer events) 0.85 over 2.2 years in FOURIER and 0.75 for first heart attack, ischemic stroke (stroke from a blocked artery) or coronary death over 4.6 years (6.2% vs 8.0% at 5 years) in VESALIUS-CV; alirocumab HR 0.85 over 2.8 years in ODYSSEY OUTCOMES; alirocumab versus evolocumab relative risk 0.99 for major events in a network meta-analysis.

Medium 🟩 🟩

Coronary Plaque Regression

Adding either antibody to a statin shrinks coronary plaque measured by intravascular ultrasound (a catheter-based image of the artery wall). GLAGOV tested evolocumab in stable coronary disease; PACMAN-AMI tested alirocumab started within 24 hours of a heart attack and also found less plaque fat and thicker fibrous caps (the protective lid over plaque). Evidence rests mainly on one industry-supported trial per drug, and plaque volume is an imaging marker linked to, but not a substitute for, clinical events.

Magnitude: Percent atheroma volume (share of the artery wall occupied by plaque) changed −0.95% vs +0.05% with evolocumab over 76 weeks in GLAGOV; −2.13% vs −0.92% with alirocumab over 52 weeks, with fibrous caps thickening 62.7 vs 33.2 μm, in PACMAN-AMI.

Fewer Limb Artery Events

In FOURIER, evolocumab reduced major adverse limb events (sudden loss of blood flow to a limb, major amputation, or an urgent stent or bypass to restore flow), with lower achieved LDL tracking lower limb risk down to below 10 mg/dL. Patients with peripheral artery disease (narrowed leg arteries) also gained larger absolute reductions in heart attack and stroke. The evidence is a prespecified analysis of a single evolocumab trial.

Magnitude: HR 0.58 for major adverse limb events across all FOURIER patients; absolute reduction in the primary endpoint 3.5% with peripheral artery disease vs 1.6% without (Bonaca et al., 2018).

Fewer Venous Blood Clots

Evolocumab was associated with fewer venous thromboembolism events (clots in deep veins or the lungs) in a post hoc (after-the-fact) FOURIER analysis, with benefit emerging after the first year and concentrated in people with higher Lp(a). Pooling FOURIER with ODYSSEY OUTCOMES pointed to a class effect shared by alirocumab. The finding is post hoc and hypothesis-generating.

Magnitude: Evolocumab HR 0.71 overall and 0.54 beyond year 1; pooled evolocumab–alirocumab HR 0.69 (Marston et al., 2020).

Low 🟩

Lower All-Cause Mortality ⚠️ Conflicted

Alirocumab reduced all-cause death in ODYSSEY OUTCOMES, a nominal result outside the trial’s planned testing order, in higher-risk patients after acute coronary syndrome. Evolocumab showed no mortality reduction in FOURIER, and network meta-analyses disagree. Net reading: a possible but unproven survival edge for alirocumab, plausibly reflecting population differences.

Magnitude: Alirocumab all-cause death HR 0.85 (3.5% vs 4.1%) in Steg et al., 2019; evolocumab cardiovascular death HR 0.77 during FOURIER-OLE; alirocumab versus evolocumab relative risk 0.80 in Guedeney et al., 2021 but 0.84 (not significant) in Xu et al., 2025; evolocumab cardiovascular death relative risk 1.20 (not significant) after readjudication.

Lipoprotein(a) Lowering

Both drugs lower Lp(a) by roughly a quarter. In ODYSSEY OUTCOMES, alirocumab’s Lp(a) reduction independently predicted fewer events; in FOURIER, evolocumab’s coronary benefit was larger above median Lp(a). Evidence is post hoc and indirect.

Magnitude: Evolocumab lowered Lp(a) by a median 26.9%, with coronary HR 0.77 above vs 0.93 below median Lp(a) (O’Donoghue et al., 2019); each 1 mg/dL Lp(a) reduction with alirocumab carried HR 0.994 (Bittner et al., 2020).

Slower Aortic Valve Narrowing

In an exploratory FOURIER analysis, evolocumab-treated patients had fewer aortic stenosis events (new or worsening aortic valve narrowing, or valve replacement) after the first year, plausibly through Lp(a) lowering. Only 63 events occurred, and evidence is limited to evolocumab.

Magnitude: Overall HR 0.66 (not significant); HR 0.48 after year 1 (Bergmark et al., 2020).

Speculative 🟨

Enhanced Anti-Tumor Immunity

In mice, PCSK9-blocking antibodies made tumors more visible to immune cells and strengthened checkpoint immunotherapy (drugs releasing immune brakes) (Liu et al., 2020). The basis is animal only.

Benefit-Modifying Factors

  • LDL-receptor genetics: Both drugs work by preserving LDL receptors, encoded by the LDLR gene. In homozygous familial hypercholesterolemia (two faulty copies), evolocumab lowered LDL only 31% (TESLA Part B); people with no functional receptors respond minimally.
  • Lp(a) level and LPA genotype: Inherited high Lp(a), set largely by the LPA gene (which encodes the apolipoprotein(a) protein), was linked to greater event reduction with evolocumab (O’Donoghue et al., 2019) and alirocumab (Bittner et al., 2020).
  • Baseline LDL cholesterol: Absolute benefit rises with starting LDL. Alirocumab’s mortality signal centered on baseline LDL of 100 mg/dL or more (HR 0.71; Steg et al., 2019); evolocumab’s relative benefit held in FOURIER’s lowest LDL quartile (Sabatine et al., 2017).
  • Sex: Relative risk reductions were similar in women and men with evolocumab (Sever et al., 2021) and alirocumab (Vallejo-Vaz et al., 2018), although women on alirocumab reached higher on-treatment LDL than men.
  • Diabetes: Patients with diabetes gained about twice the absolute event reduction with alirocumab (Ray et al., 2019), and evolocumab’s relative benefit was consistent with or without diabetes (Sabatine et al., 2017).
  • Existing vascular disease: Recent acute coronary syndrome, peripheral artery disease or multivessel disease raise baseline risk and therefore absolute benefit; people without known plaque gain less in absolute terms.
  • Age: Relative benefit was consistent across ages. With alirocumab, the number needed to treat (people treated to prevent one event) fell from 43 at age 45 to 12 at age 85, because older people carry higher risk (Sinnaeve et al., 2020).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Reactions

Redness, pain, itching, swelling or bruising at the injection site is the most consistent adverse effect of both antibodies, documented across outcome trials and both prescribing labels. Reactions are usually mild and rarely lead to stopping. Indirect comparison suggests alirocumab causes somewhat more, the 300 mg monthly alirocumab regimen (two injections) produced the highest rates, and people who develop antibodies against alirocumab report more reactions.

Magnitude: Evolocumab 2.1% vs 1.6% in FOURIER; alirocumab 3.8% vs 2.1% in ODYSSEY OUTCOMES; alirocumab about 27% more than evolocumab by indirect comparison; 16.6% with alirocumab 300 mg every 4 weeks vs 7.9% with placebo (Praluent prescribing information).

Medium 🟥 🟥

Upper Respiratory Symptoms and Influenza-Like Illness

Nasopharyngitis (common-cold symptoms), upper respiratory tract infection, influenza and back pain were the most common adverse events with evolocumab in its 52-week trial, and influenza-like illness is listed from post-marketing use of both drugs. The excess over placebo is small and was near-absent in large outcome trials, so causality is uncertain.

Magnitude: Upper respiratory infection 9.3% vs 6.3% and influenza 7.5% vs 6.3% with evolocumab over 52 weeks (DESCARTES; Repatha prescribing information); influenza 6% vs 5% with alirocumab in pooled trials (Praluent prescribing information).

Muscle Aches

Myalgia (muscle pain) was reported slightly more often than with placebo for alirocumab in ODYSSEY LONG TERM and ODYSSEY OUTCOMES and for evolocumab in its 52-week trial. The excess is small and unlike statin-related muscle injury. In people with confirmed statin muscle intolerance, muscle symptoms were not more frequent on evolocumab than on ezetimibe, and were less frequent on alirocumab than on atorvastatin rechallenge.

Magnitude: Alirocumab 5.4% vs 2.9% (ODYSSEY LONG TERM); evolocumab 20.7% vs ezetimibe 28.8% in statin-intolerant patients (GAUSS-3); alirocumab versus atorvastatin HR 0.61 for muscle events (ODYSSEY ALTERNATIVE).

Hypersensitivity Reactions

Rash, pruritus (itching), urticaria (hives) and rare angioedema (deep swelling of skin, lips or airway) occur with both drugs; alirocumab’s label also lists hypersensitivity vasculitis (allergic inflammation of small blood vessels) and reactions requiring hospitalization. Evidence comes from pooled controlled trials and post-marketing reports. Indirect comparison found no difference in systemic allergic reactions between the agents.

Magnitude: Hypersensitivity 5.1% vs 4.7% with evolocumab and 8.6% vs 7.8% with alirocumab versus placebo, with allergy-related discontinuation 0.6% vs 0.2% on alirocumab (prescribing information for Repatha and Praluent); no between-drug difference in systemic allergy (Guedeney et al., 2021).

Low 🟥

New-Onset Diabetes ⚠️ Conflicted

Genetic studies predict modestly higher diabetes risk with lifelong PCSK9 reduction, but outcome trials of both drugs found no excess new diabetes. One meta-analysis reported early worsening of existing diabetes with evolocumab. Net reading: no measurable risk during trial follow-up, with long-term uncertainty.

Magnitude: Genetic odds ratio (odds of diabetes relative to non-carriers) 1.29 per 1 mmol/L lower LDL (Schmidt et al., 2017); trial HR 1.05 for evolocumab (Sabatine et al., 2017) and 1.00 for alirocumab (Ray et al., 2019).

Neurocognitive Complaints ⚠️ Conflicted

Early extension studies of evolocumab and ODYSSEY LONG TERM reported slightly more memory or confusion complaints. The randomized EBBINGHAUS cognitive-testing trial of evolocumab and a 21-trial meta-analysis found no difference. Net reading: early signals were not confirmed by controlled testing.

Magnitude: Neurocognitive events 1.2% vs 0.5% with alirocumab (ODYSSEY LONG TERM); no difference in executive function over 19 months (EBBINGHAUS); pooled relative risk 1.01 (Hirsh Raccah et al., 2021).

Anti-Drug Antibodies and Reduced Response

About 5% of alirocumab users in ODYSSEY OUTCOMES developed antibodies against the drug, a few of them neutralizing ones that blunted LDL lowering. Evolocumab produced binding antibodies in 0.3% and no neutralizing antibodies. Data come from trial antibody testing reported in the labels.

Magnitude: Alirocumab anti-drug antibodies 5.5% and neutralizing 0.5% in ODYSSEY OUTCOMES (Praluent prescribing information); evolocumab 0.3% binding, 0% neutralizing (Repatha prescribing information).

Liver Enzyme Elevations ⚠️ Conflicted

Alirocumab’s label reports slightly more liver-enzyme abnormalities than placebo, occasionally leading to discontinuation. A large meta-analysis of both drugs found no significant increase. Net reading: any liver effect is small and inconsistent.

Magnitude: Liver-related disorders 2.5% vs 1.8% and liver enzymes above 3 times normal 1.7% vs 1.4% with alirocumab (Praluent prescribing information); pooled odds ratio 0.91, not significant (Rivera et al., 2024).

Consequences of Very Low LDL Cholesterol

Both drugs often push LDL below 25 mg/dL, raising theoretical concerns about hemorrhagic stroke (bleeding into the brain), cataracts, hormones and vitamin E. Controlled data show no excess at very low LDL, but decades-long exposure is unstudied.

Magnitude: No association between achieved LDL (down to below 0.2 mmol/L, about 8 mg/dL) and any of 10 prespecified safety events with evolocumab (Giugliano et al., 2017); cataract odds ratio 0.96 across trials of both drugs (Masson et al., 2019); sex hormones unchanged and cortisol only slightly higher, with no adverse hormonal effects, with evolocumab (Blom et al., 2015).

Speculative 🟨

Fetal Immune Effects

Both antibodies cross the placenta. In monkeys, alirocumab exposure before birth suppressed infant antibody responses; evolocumab was not tested for this. Human pregnancy data are insufficient; the basis is animal only.

Risk-Modifying Factors

  • Genetic variants: No gene variant affecting drug handling is known to alter safety, because neither drug is metabolized by CYP enzymes. LDLR and LPA genotypes change how well the drugs work, not their side effects.
  • Latex sensitivity: Some evolocumab syringes and autoinjectors contain dry natural rubber (a latex derivative) in the needle cover; a latex-free presentation exists. Alirocumab pens are not described as containing latex.
  • Baseline LDL cholesterol: Low starting LDL produces very low on-treatment LDL. Trials found no safety gradient down to below 10 mg/dL, but long-term data at such levels are sparse.
  • Baseline glucose: Prediabetes did not raise new-onset diabetes risk with evolocumab (HR 1.00; Sabatine et al., 2017) or alirocumab (HR 0.97; Ray et al., 2019), so baseline HbA1c (average blood sugar over about 3 months) mainly guides monitoring frequency.
  • Sex: Adverse events were more common in women overall in FOURIER, without a sex-specific excess versus placebo (Sever et al., 2021). Women who could become pregnant face the placental-transfer question.
  • Kidney and liver impairment: Evolocumab exposure is lower in severe kidney failure and mild-to-moderate liver impairment, with preserved PCSK9 suppression; alirocumab has no data in severe kidney or liver impairment.
  • Age: Adverse events rise with age but showed no drug-specific excess in older trial participants; reduced hand strength or vision can complicate self-injection.

Key Interactions & Contraindications

  • Statins (atorvastatin, rosuvastatin, simvastatin) — monitor: Statins raise PCSK9, shortening alirocumab’s half-life to about 12 days and lowering evolocumab exposure about 20%; not clinically meaningful. Consequence: intended additive LDL lowering. Mitigation: LDL measured just before the next dose on monthly regimens.
  • Other LDL-lowering drugs (ezetimibe, bempedoic acid) — monitor: Additive LDL lowering without changes in each other’s blood levels; combined therapy can reach very low LDL. Mitigation: lipid recheck 4–12 weeks after any change.
  • Other PCSK9-directed drugs (inclisiran, enlicitide, lerodalcibep) — avoid combining: Duplicate mechanism with no safety or efficacy data for concurrent use, including evolocumab with alirocumab; consequence: unknown added risk and cost. Mitigation: when switching, the new agent starts at the old one’s next due dose.
  • CYP-metabolized medications (warfarin, clopidogrel, cyclosporine) — no interaction expected: Alirocumab did not change statin levels handled by CYP3A4 and CYP2C9 (liver enzymes metabolizing many drugs) or P-glycoprotein (a drug-exporting cell pump). Consequence: none known; no dose adjustment.
  • Over-the-counter medications (ibuprofen, acetaminophen, antihistamines such as cetirizine) — no known interaction: No effect on drug levels is expected. Antihistamines can ease mild injection-site itching but may mask early hypersensitivity. Mitigation: facial or throat swelling treated as urgent.
  • Red yeast rice — caution: Contains monacolin K, chemically identical to lovastatin, so it adds statin-like LDL lowering and statin-type muscle and liver risks, with variable product potency. Mitigation: a prescribed statin offers standardized dosing; lipid and liver checks if used.
  • Berberine — monitor: Lowers LDL partly by reducing PCSK9 production, giving an additive effect; gastrointestinal upset is common. Mitigation: LDL recheck after adding it.
  • Plant sterols and stanols, psyllium fiber — monitor (additive): Reduce intestinal cholesterol absorption for modest extra LDL lowering on top of either antibody. Consequence: beneficial additive effect. Mitigation: none needed beyond routine lipid checks.
  • LDL apheresis (filtering LDL from the blood) — monitor timing: Alirocumab can be given without regard to apheresis timing; evolocumab 420 mg every 2 weeks is given after the apheresis session is complete. Consequence: none known when labels’ sequencing is followed.

Populations who should avoid Evolocumab vs. Alirocumab:

  • Anyone with a prior serious hypersensitivity reaction (such as angioedema) to evolocumab, alirocumab or their inactive ingredients — absolute contraindication for the offending drug
  • People with latex allergy — avoid evolocumab presentations with dry natural rubber needle covers
  • Pregnancy or planned pregnancy — insufficient human data; both antibodies cross the placenta
  • Children under 10 years (evolocumab) or under 8 years (alirocumab) — safety and efficacy not established
  • Homozygous familial hypercholesterolemia with receptor-negative LDLR variants (below 2% residual LDL-receptor activity) — minimal efficacy expected
  • Severe kidney impairment (eGFR, estimated glomerular filtration rate, a kidney-function measure, below 30 mL/min/1.73 m²) or severe liver impairment (Child-Pugh class C, the most severe grade of liver-disease scoring) — no alirocumab data; use with caution

Risk Mitigation Strategies

  • Injection technique: Warming the pen or syringe to room temperature for 30–40 minutes, rotating abdomen, thigh and upper-arm sites, and avoiding bruised or scarred skin reduce injection-site reactions.
  • Lower-reaction regimen: People with repeated site reactions on alirocumab 300 mg every 4 weeks can use 75–150 mg every 2 weeks (reaction rates 9.6% vs 16.6%) or switch to evolocumab.
  • Latex-free presentation: People with latex sensitivity use a latex-free evolocumab presentation or alirocumab; prevents latex-triggered allergic reactions.
  • Glucose monitoring: HbA1c at baseline and yearly, or every 3–6 months with existing diabetes; addresses the genetic diabetes signal and early worsening reported with evolocumab.
  • Hypersensitivity action plan: Stopping the drug and seeking urgent care for facial, lip or throat swelling or widespread hives prevents progression of angioedema or vasculitis.
  • Loss-of-response check: An LDL recheck 4–12 weeks after starting, then every 6–12 months, detects an unexplained LDL rise on alirocumab that may signal neutralizing antibodies and justify a switch to evolocumab.
  • Pregnancy planning: Stopping at least five half-lives (roughly 2–3 months) before planned conception limits fetal antibody exposure.
  • Optional LDL floor: Those uneasy about LDL below 25 mg/dL can follow ODYSSEY-style down-titration (alirocumab 150 → 75 mg every 2 weeks); addresses the untested decades-long very-low-LDL question.
  • Muscle symptom work-up: Creatine kinase (a muscle-damage enzyme) testing when muscle pain persists beyond 2–4 weeks distinguishes drug myalgia from statin- or exercise-related injury.

Therapeutic Protocol

  • Evolocumab standard dosing: 140 mg every 2 weeks or 420 mg once monthly (three consecutive 140 mg injections within 30 minutes), fixed dose without titration, as used in FOURIER and VESALIUS-CV.
  • Alirocumab standard dosing: 75 mg every 2 weeks or 300 mg every 4 weeks, increased to 150 mg every 2 weeks if LDL response is inadequate; 150 mg every 2 weeks for homozygous familial hypercholesterolemia or apheresis.
  • Treat-to-target titration: Popularized by the ODYSSEY OUTCOMES investigators (Schwartz, Steg): alirocumab is titrated to an LDL of 25–50 mg/dL, stepping down when LDL falls below 25 mg/dL twice.
  • Fixed-dose “lower is better”: Championed by the FOURIER investigators (Sabatine and colleagues at Brigham and Women’s Hospital): full dose without an LDL floor, since risk kept falling at very low LDL (Giugliano et al., 2017).
  • Stepwise guideline sequence: European cardiology and atherosclerosis societies sequence statin, ezetimibe, then a PCSK9 antibody to reach LDL below 55 mg/dL at very high risk; members earn no direct revenue from these prescriptions, though panelists’ manufacturer ties exist.
  • Early intensive apoB targeting: Peter Attia has described personally combining evolocumab with bempedoic acid and ezetimibe to keep apoB below 40 mg/dL, extrapolating from genetics and trial dose–response rather than outcome trials.
  • Choosing between the two: With no large head-to-head trial, choice rests on access, cost, device, injection count, antibody-reaction history and dosing preference; switching is straightforward.
  • Time of day: No food effect or circadian timing is known; any consistent time works. A dose missed by up to 7 days is given and the schedule resumed.
  • Half-life and interval: Evolocumab’s 11–17 days and alirocumab’s 17–20 days (about 12 with statins) permit 2- or 4-week intervals; LDL can drift upward late in monthly intervals.
  • Single vs split dosing: Every-2-week dosing uses one injection and gives steadier LDL; monthly doses are split into several injections at one sitting (three for evolocumab, two for alirocumab).
  • Genetic polymorphisms: In homozygous familial hypercholesterolemia, evolocumab starts at 420 mg monthly and rises to every 2 weeks after 12 weeks if needed; LDLR receptor-negative patients need receptor-independent therapies. High LPA-driven Lp(a) favors starting earlier.
  • Sex differences: No sex-specific dosing. Women on alirocumab reached higher on-treatment LDL, which may justify earlier up-titration; contraception planning applies for women who could become pregnant.
  • Age considerations: No age-based dose change; older adults gain larger absolute benefit. Children and adolescents with heterozygous familial hypercholesterolemia use evolocumab from age 10 or weight-based alirocumab from age 8.
  • Baseline biomarkers: Baseline LDL, apoB and Lp(a) set expected absolute benefit; LDL of 100 mg/dL or more and high Lp(a) predicted larger gains. Response is judged by percentage fall from baseline.
  • Pre-existing conditions: Diabetes, peripheral artery disease and recent acute coronary syndrome need no dose change but raise absolute benefit; severe kidney or liver impairment warrants closer LDL follow-up.

Discontinuation & Cycling

  • Lifelong intent: Both drugs are designed for indefinite use; benefit depends on cumulative LDL reduction, and FOURIER-OLE showed delayed starters did not catch up to early starters (O’Donoghue et al., 2022).
  • Withdrawal effects: No withdrawal syndrome is known; LDL returns toward baseline over several weeks as the antibody clears (free PCSK9 recovers once drug levels fall).
  • Tapering: No taper is required; stopping abruptly is safe. Dose reduction is used only for very low LDL (alirocumab 150 → 75 mg every 2 weeks).
  • Cycling: No rationale supports cycling; efficacy does not wane with continuous use (up to 8.4 years with evolocumab), and pauses forfeit cumulative benefit.
  • Switching agents: Moving between evolocumab and alirocumab (for injection-site reactions, antibodies, cost or access) needs no washout; the new drug starts when the next dose of the old one is due.
  • Stopping for pregnancy: Treatment is typically stopped ahead of planned conception or on confirmed pregnancy, given placental transfer and insufficient human data.

Sourcing and Quality

  • Regulated biologics only: Evolocumab (Repatha, Amgen) and alirocumab (Praluent, Regeneron in the United States, Sanofi elsewhere) are prescription biologics (protein drugs made in living cells); no compounded versions exist, so purity rests on FDA-regulated manufacturing.
  • Authorized channels: Licensed pharmacies, specialty pharmacies and manufacturer programs are the reliable sources; unregulated online sellers cannot guarantee authenticity or cold-chain handling of a protein drug.
  • What to look for: Intact sealed packaging, an unexpired date, and a clear, colorless to pale-yellow solution without cloudiness or particles; devices that were frozen or left unrefrigerated beyond the allowed period are discarded.
  • Storage and cold chain: Both drugs are stored refrigerated at 2–8 °C in the original carton; either may be kept at room temperature up to 25 °C for up to 30 days, after which it is used or discarded.
  • Device presentations: Evolocumab comes as a SureClick autoinjector, prefilled pen and prefilled syringe (some with latex); alirocumab comes as 75 mg and 150 mg prefilled pens.
  • Direct-to-patient pricing: Amgen’s AmgenNow program sells Repatha at $239 per month without insurer prior authorization; Praluent is accessed mainly through insurance, copay cards and specialty pharmacies.
  • Third-party testing: Not applicable to FDA-licensed biologics, which undergo lot release testing; independent supplement-style testing does not exist for these drugs.

Practical Considerations

  • Time to effect: LDL reaches its low point within 2 weeks (evolocumab 140 mg) to 3 weeks (420 mg); plaque changes appear at 12–18 months, and event curves separate after roughly 1 year.
  • Common pitfalls: Measuring LDL mid-interval on monthly dosing, injecting cold medication, lapsed insurance reauthorizations, missed doses during travel, and expecting a response in LDL-receptor-negative familial hypercholesterolemia.
  • Regulatory status: FDA-approved since 2015; 2025 label updates cover adults at increased cardiovascular risk (evolocumab, August 2025; alirocumab, October 2025). Use in low-risk adults with average LDL lacks outcome-trial support.
  • Cost and accessibility: Repatha costs $239 per month through AmgenNow; Praluent’s list price is about $5,850 per year. Insurers commonly require prior authorization and step therapy through statins and ezetimibe.
  • Payer incentives: Insurers and national health systems have a systematic incentive to favor generic statins and ezetimibe costing a few dollars monthly, and pharmacy benefit managers have traded exclusive formulary placement for rebates — structural pressures on guidelines, access and research priorities.
  • Injection burden: Every-2-week regimens mean 26 injection days per year; monthly regimens mean 12 sessions but two or three injections each.
  • Travel: Both drugs tolerate up to 30 days at room temperature, so an insulated pouch suffices for most trips; air travel requires the pens in carry-on luggage.

Interaction with Foundational Habits

  • Sleep: No direct interaction; no sleep disruption was reported in the outcome trials, and injections can be given at any hour. Good sleep supports cardiovascular risk reduction independently of either drug.
  • Nutrition: Potentiating. A diet low in saturated fat and rich in soluble fiber adds LDL lowering. With evolocumab, absolute vitamin E fell 16% but rose when normalized to cholesterol, and red-cell vitamin E was unchanged (Blom et al., 2015), so routine supplementation is not required.
  • Exercise: None (no blunting), complementary; unlike statins, neither drug shows a muscle-toxicity pattern, and muscle symptoms in statin-intolerant people were no more frequent than with ezetimibe (GAUSS-3). Exercise adds independent cardiovascular benefit; no timing restrictions relative to injections are known.
  • Stress management: No direct interaction. Evolocumab did not alter the stress-hormone axis (Blom et al., 2015): cortisol rose slightly while adrenocorticotropic hormone (the pituitary signal that drives cortisol) and their ratio were unchanged. Stress reduction lowers cardiovascular risk independently.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a lipid panel with LDL cholesterol and apoB establishes the reference point, alongside a once-in-a-lifetime Lp(a) measurement, HbA1c, liver enzymes and kidney function. A coronary artery calcium score (a computed tomography measure of calcified plaque) or coronary computed tomography angiography helps define baseline plaque burden and absolute risk. People with suspected familial hypercholesterolemia benefit from genetic testing to identify receptor-negative variants.

Ongoing monitoring: Lipids are rechecked 4–12 weeks after starting or changing dose, measured just before the next injection on monthly regimens, then every 6–12 months. HbA1c is repeated yearly, or every 3–6 months in diabetes. Liver enzymes and creatine kinase are checked if symptoms arise, and plaque imaging is repeated no sooner than every 2–3 years.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol Below 55 mg/dL; many longevity practitioners aim lower, toward 30–40 mg/dL Primary treatment response Conventional “desirable” is below 100 mg/dL; best measured just before the next dose on monthly dosing; direct LDL measurement is more accurate than calculated LDL below 70 mg/dL
ApoB Below 60 mg/dL; aggressive targets below 40 mg/dL Counts artery-clogging particles Conventional reference often below 90–100 mg/dL; better than LDL when triglycerides are high; non-fasting sample acceptable
Non-HDL cholesterol Below 85 mg/dL Captures all artery-clogging cholesterol Conventional target below 130 mg/dL; best paired with apoB
Lp(a) Below 75 nmol/L (about 30 mg/dL) Inherited risk; predicts larger benefit Conventional risk threshold about 125 nmol/L (50 mg/dL); measured once at baseline; about 25% fall expected on either drug; nmol/L assays preferred
HbA1c Below 5.4% Tracks the genetic diabetes signal Conventional normal is below 5.7%; best paired with fasting glucose (optimal 70–90 mg/dL, conventional below 100 mg/dL)
hs-CRP Below 1.0 mg/L Residual inflammatory risk not addressed by these drugs hs-CRP is high-sensitivity C-reactive protein, an inflammation marker; conventional cut-off below 3 mg/L; unreliable during acute illness
Liver enzymes (ALT, AST) ALT below 25 U/L Alirocumab label notes mild elevations ALT and AST are alanine and aspartate aminotransferase; conventional upper limit about 40–55 U/L; checked if symptoms arise or with multiple lipid drugs
Kidney function (creatinine, eGFR) eGFR above 90 mL/min/1.73 m² Severe impairment changes exposure and data coverage Conventional reference above 60 mL/min/1.73 m²
Creatine kinase No established target; track change from the individual’s own baseline Evaluates persistent muscle pain Tested only if symptoms arise; strenuous exercise within 48 hours raises values
Coronary artery calcium score or coronary computed tomography angiography Calcium score of 0; stable or shrinking non-calcified plaque Plaque burden and trajectory Repeat imaging typically no sooner than 2–3 years; lipid-lowering can increase calcium density as plaque stabilizes

Qualitative markers:

  • Injection-site comfort and absence of rash, hives or swelling
  • Muscle comfort and exercise tolerance
  • Subjective memory and cognitive clarity
  • Adherence: missed or delayed doses per quarter
  • Exertional chest discomfort or breathlessness (should remain absent or decline)
  • Ease of self-injection and device handling

Emerging Research

  • Very early evolocumab after heart attack: NCT05284747 (EVOLVE-MI) is an Amgen-sponsored pragmatic (run within routine care) phase 4 (post-approval) trial of 6,019 patients hospitalized with heart attack, testing evolocumab plus routine care against routine care on total heart attack, ischemic stroke, revascularization (procedures restoring blood flow) and all-cause death; completion expected 2027.
  • Weekly alirocumab dosing: NCT07477704 is a Regeneron phase 2 dose-ranging study in 420 adults testing weekly alirocumab, with percent LDL change as primary endpoint; it may yield a new regimen for the older antibody.
  • Evolocumab for early, subclinical plaque: NCT07803679 is an Amgen phase 4 trial in 308 people with subclinical atheroma (plaque not yet causing symptoms), measuring non-calcified plaque volume by artificial-intelligence-quantified coronary computed tomography angiography at 72 weeks — directly relevant to prevention-minded adults.
  • Aortic valve stenosis prevention: NCT04968509, a phase 3 trial, randomizes 160 patients with mild-to-moderate calcific aortic stenosis to a PCSK9 inhibitor plus statin versus statin, with annual change in peak aortic jet velocity (blood-flow speed across the valve, a measure of narrowing) as primary endpoint, testing FOURIER’s exploratory valve signal.
  • Oral competitor: Enlicitide, a once-daily oral PCSK9 inhibitor, lowered LDL about 56 percentage points versus placebo (Navar et al., 2026); its 14,550-participant phase 3 outcome trial NCT06008756 could displace injectable antibodies for many users.
  • Mortality data integrity (could weaken the case): Independent readjudication of FOURIER deaths (Erviti et al., 2022) and baseline-imbalance concerns across both drugs’ trials (van Bruggen et al., 2024) call for full patient-level data release.
  • Head-to-head comparison gap: No large randomized outcome trial compares the two antibodies directly; Sabouret et al., 2026 call for one in high-LDL, high-risk patients, which could settle the alirocumab mortality question.
  • One-time gene editing: Base-editing (precise single-letter DNA changes) approaches aim to permanently switch off liver PCSK9, reproducing lifelong genetic deficiency; a first-in-human trial of VERVE-102 reported deep LDL lowering (Vafai et al., 2026; Peter Attia’s review); success would reframe both antibodies as bridging therapies.

Conclusion

Evolocumab and alirocumab are injectable antibodies that block the same liver protein and sharply cut the cholesterol-carrying particles that drive artery plaque, on top of standard treatment. For health-focused adults with established artery disease, diabetes, inherited high cholesterol or high measured risk, both reduce heart attacks, strokes and artery procedures, and both can shrink existing plaque. On these core effects the two drugs look interchangeable.

The main points of difference are narrower. Alirocumab has a possible survival edge from one trial, but it rests on a result outside the trial’s planned analysis and on a sicker, more recently hospitalized population; evolocumab has the larger body of long-term safety follow-up and newer evidence in people who have not yet had a heart attack or stroke. Alirocumab tends to cause more injection-site reactions and more frequent immune responses against the drug, while evolocumab carries a latex issue in some devices. Side effects of both are generally mild, and early worries about memory, diabetes and very low cholesterol have not been borne out in controlled studies, though lifelong use remains unstudied.

The evidence base is large but was mostly funded by the two manufacturers, and guideline groups that recommend these drugs include experts with company ties, even though their members do not profit directly from prescriptions. Independent reanalyses have questioned parts of the published death data. Cost, insurer rules and device preference often shape which drug is used more than any proven difference between them.

Top - Benefits - Risks - Protocol